Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where William Salomon is active.

Publication


Featured researches published by William Salomon.


Cell | 2015

Single-Molecule Imaging Reveals that Argonaute Reshapes the Binding Properties of Its Nucleic Acid Guides

William Salomon; Samson M. Jolly; Melissa J. Moore; Phillip D. Zamore; Victor Serebrov

Argonaute proteins repress gene expression and defend against foreign nucleic acids using short RNAs or DNAs to specify the correct target RNA or DNA sequence. We have developed single-molecule methods to analyze target binding and cleavage mediated by the Argonaute:guide complex, RISC. We find that both eukaryotic and prokaryotic Argonaute proteins reshape the fundamental properties of RNA:RNA, RNA:DNA, and DNA:DNA hybridization—a small RNA or DNA bound to Argonaute as a guide no longer follows the well-established rules by which oligonucleotides find, bind, and dissociate from complementary nucleic acid sequences. Argonautes distinguish substrates from targets with similar complementarity. Mouse AGO2, for example, binds tighter to miRNA targets than its RNAi cleavage product, even though the cleaved product contains more base pairs. By re-writing the rules for nucleic acid hybridization, Argonautes allow oligonucleotides to serve as specificity determinants with thermodynamic and kinetic properties more typical of RNA-binding proteins than of RNA or DNA.


Biochemical Journal | 2011

Glucan particles for selective delivery of siRNA to phagocytic cells in mice.

Gregory J. Tesz; Myriam Aouadi; Matthieu Prot; Sarah M. Nicoloro; Emilie Boutet; Shinya U. Amano; Anca Goller; Mengxi Wang; Chang-An Guo; William Salomon; Joseph V. Virbasius; Rebecca Baum; Mark J. O'Connor; Ernesto Soto; Gary R. Ostroff; Michael P. Czech

Phagocytic macrophages and dendritic cells are desirable targets for potential RNAi (RNA interference) therapeutics because they often mediate pathogenic inflammation and autoimmune responses. We recently engineered a complex 5 component glucan-based encapsulation system for siRNA (small interfering RNA) delivery to phagocytes. In experiments designed to simplify this original formulation, we discovered that the amphipathic peptide Endo-Porter forms stable nanocomplexes with siRNA that can mediate potent gene silencing in multiple cell types. In order to restrict such gene silencing to phagocytes, a method was developed to entrap siRNA-Endo-Porter complexes in glucan shells of 2-4 μm diameter in the absence of other components. The resulting glucan particles containing fluorescently labelled siRNA were readily internalized by macrophages, but not other cell types, and released the labelled siRNA into the macrophage cytoplasm. Intraperitoneal administration of such glucan particles containing siRNA-Endo-Porter complexes to mice caused gene silencing specifically in macrophages that internalized the particles. These results from the present study indicate that specific targeting to phagocytes is mediated by the glucan, whereas Endo-Porter peptide serves both to anchor siRNA within glucan particles and to catalyse escape of siRNA from phagosomes. Thus we have developed a simplified siRNA delivery system that effectively and specifically targets phagocytes in culture or in intact mice.


Nucleic Acids Research | 2010

Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC

William Salomon; Karen Bulock; Jennifer Lapierre; Pamela Pavco; Tod M. Woolf; Joanne Kamens

Chemical modification of RNA duplexes can provide practical advantages for RNA interference (RNAi) triggering molecules including increased stability, safety and specificity. The impact of nucleotide modifications on Dicer processing, RISC loading and RNAi-mediated mRNA cleavage was investigated with duplexes ≥25 bp in length. It is known that dsRNAs ≥25 bp are processed by Dicer to create classic 19-bp siRNAs with 3′-end overhangs. We demonstrate that the presence of minimal modification configurations on longer RNA duplexes can block Dicer processing and result in the loading of the full-length guide strand into RISC with resultant mRNA cleavage at a defined site. These longer, modified duplexes can be highly potent gene silencers, with EC50s in the picomolar concentration range, demonstrating that Dicer processing is not required for incorporation into RISC or potent target silencing.


RNA | 2011

Potent and systematic RNAi mediated silencing with single oligonucleotide compounds

Jennifer Lapierre; William Salomon; James Cardia; Karen Bulock; Jessica T. Lam; Glenna Ford; Bernice Smith-Anzures; Tod Woolf; Joanne Kamens; Anastasia Khvorova; Dmitry Samarsky

RNA interference (RNAi) has been established as an important tool for functional genomics studies and has great promise as a therapeutic intervention for human diseases. In mammalian cells, RNAi is conventionally induced by 19-27-bp RNA duplexes generated by hybridization of two complementary oligonucleotide strands (oligos). Here we describe a novel class of RNAi molecules composed of a single 25-28-nucleotide (nt) oligo. The oligo has a 16-nt mRNA targeting region, followed by an additional 8-10 nt to enable self-dimerization into a partially complementary duplex. Analysis of numerous diverse structures demonstrates that molecules composed of two short helices separated by a loop can efficiently enter and activate the RNA-induced silencing complex (RISC). This finding enables the design of highly effective single-oligo compounds for any mRNA target.


Nucleic Acids Research | 2018

Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo

Matthew R. Hassler; Anton A. Turanov; Julia F. Alterman; Reka A. Haraszti; Andrew H. Coles; Maire F. Osborn; Dimas Echeverria; Mehran Nikan; William Salomon; Loic Roux; Bruno M.D.C. Godinho; Sarah M. Davis; David V. Morrissey; Phillip D. Zamore; S. Ananth Karumanchi; Melissa J. Moore; Neil Aronin; Anastasia Khvorova

Abstract Small interfering RNA (siRNA)-based drugs require chemical modifications or formulation to promote stability, minimize innate immunity, and enable delivery to target tissues. Partially modified siRNAs (up to 70% of the nucleotides) provide significant stabilization in vitro and are commercially available; thus are commonly used to evaluate efficacy of bio-conjugates for in vivo delivery. In contrast, most clinically-advanced non-formulated compounds, using conjugation as a delivery strategy, are fully chemically modified (100% of nucleotides). Here, we compare partially and fully chemically modified siRNAs in conjugate mediated delivery. We show that fully modified siRNAs are retained at 100x greater levels in various tissues, independently of the nature of the conjugate or siRNA sequence, and support productive mRNA silencing. Thus, fully chemically stabilized siRNAs may provide a better platform to identify novel moieties (peptides, aptamers, small molecules) for targeted RNAi delivery.


Cell | 2012

Argonaute divides its RNA guide into domains with distinct functions and RNA-binding properties.

Liang Meng Wee; C. Fabián Flores-Jasso; William Salomon; Phillip D. Zamore


RNA | 2011

Argonaute protein identity and pairing geometry determine cooperativity in mammalian RNA silencing

Jennifer A. Broderick; William Salomon; Sean P. Ryder; Neil Aronin; Phillip D. Zamore


Archive | 2009

Reduced size self-delivering rnai compounds

Anastasia Khvorova; William Salomon; Joanne Kamens; Dmitry Samarsky; Tod M. Woolf; James Cardia


RNA | 2013

Rapid and specific purification of Argonaute-small RNA complexes from crude cell lysates

Carlos Fabian Flores-Jasso; William Salomon; Phillip D. Zamore


Archive | 2009

Rna interference in skin indications

Anastasia Khvorova; William Salomon; Joanne Kamens; Dmitry Samarsky; Tod M. Woolf; Pamela Pavco; James Cardia

Collaboration


Dive into the William Salomon's collaboration.

Top Co-Authors

Avatar

Anastasia Khvorova

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dmitry Samarsky

University of Massachusetts Amherst

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Phillip D. Zamore

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Melissa J. Moore

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Neil Aronin

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Anca Goller

University of Massachusetts Medical School

View shared research outputs
Researchain Logo
Decentralizing Knowledge